EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia

Georgia McCaughan, Hayley Beer, Christian Bryant, P Joy Ho iD, Tracy King, Cindy Lee, Peter Mollee, H Miles Prince, Andrew Spencer, Dipti Talaulikar iD, Kate Vandyke, Nicholas Weber und 3 weitere

Internal Medicine Journal · 2025

DOI: 10.1111/imj.70148 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Internal Medicine Journal, 2025. Verfasst von Georgia McCaughan und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Advisory Committees, Disease Management, Hematopoietic Stem Cell Transplantation, Multiple Myeloma. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The survival of newly diagnosed patients with multiple myeloma has improved significantly over the past 20 years with significant therapeutic advances. Despite this, high‐dose chemotherapy followed by autologous stem cell transplantation remains the standard of care in newly diagnosed patients who are considered transplant eligible. Here, we summarise the recommendations of the Medical and Scientific Advisory Group of Myeloma Australia for patients considered suitable for high‐dose chemotherapy and autologous stem cell transplantation as part of the initial therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Advisory CommitteesDisease ManagementHematopoietic Stem Cell TransplantationMultiple MyelomaStem Cell TransplantationHumansAntineoplastic Combined Chemotherapy ProtocolsAustraliaTransplantation, Autologous

Stichwörter der Autor:innen

autologous stem cell transplantationinductionmaintenancemultiple myelomanewly diagnosed

Autor:innen und Institutionen

  • Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, UNSW Medicine and Health, Sydney, New South Wales, Australia.
  • Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Myeloma Australia, Melbourne, Victoria, Australia.
  • Institute of Haematology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
  • Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia.

ORCID-Profile: P Joy Ho, Dipti Talaulikar

Zitieren

APA

McCaughan, G., Beer, H., Bryant, C., Ho, P. J., King, T., Lee, C., Mollee, P., Prince, H. M., Spencer, A., Talaulikar, D., Vandyke, K., Weber, N., Yong, A., Harrison, S., & Quach, H. (2025). Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Internal Medicine Journal. https://doi.org/10.1111/imj.70148

Vancouver

McCaughan G, Beer H, Bryant C, Ho PJ, King T, Lee C, et al. Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Internal Medicine Journal. 2025. doi:10.1111/imj.70148

BibTeX
@article{McCaughan2025,
  author = {McCaughan, Georgia and Beer, Hayley and Bryant, Christian and Ho, P Joy and King, Tracy and Lee, Cindy and Mollee, Peter and Prince, H Miles and Spencer, Andrew and Talaulikar, Dipti and Vandyke, Kate and Weber, Nicholas and Yong, Angelina and Harrison, Simon and Quach, Hang},
  title = {Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia},
  journal = {Internal Medicine Journal},
  year = {2025},
  doi = {10.1111/imj.70148}
}
Kostenlos starten →